The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
Open accessAbstract
Purpose: Statins have potential protective effects against cancers, but no studies have focused on patients with chronic hepatitis B virus (HBV) infection. The purpose of this study was to investigate the association between the use of statins in HBV-infected patients and the risk of hepatocellular carcinoma (HCC). Patients and Methods: We conducted a population-based cohort study from the Taiwan National Health Insurance Research Database. A total of 33,413 HBV-infected patients were included as the study cohort. Each patient was individually tracked from 1997 to 2008 to identify incident cases of HCC since 1999. Subsequent use of statin, other lipid-lowering agents, aspirin, and angiotensin-converting enzyme inhibitors was identified. Cox proportional hazards regression was used to calculate the hazard ratios (HRs) and 95% CIs for the association between the use of statins and the occurrence of HCC in the HBV-infected cohort. Results: There were 1,021 HCCs in the HBV cohort during the follow-up period of 328,946 person-years; the overall incidence rate was 310.4 HCCs per 100,000 person-years. There was a dose-response relationship between statin use and the risk of HCC in the HBV cohort. The adjusted HRs were 0.66 (95% CI, 0.44 to 0.99), 0.41 (95% CI, 0.27 to 0.61), and 0.34 (95% CI, 0.18 to 0.67) for statin use of 28 to 90, 91 to 365, and more than 365 cumulative defined daily doses (cDDDs), respectively, relative to no statin use (< 28 cDDDs). Conclusion: Statin use may reduce the risk for HCC in HBV-infected patients in a dose-dependent manner. Further mechanistic research is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Validation of the national health insurance research database with ischemic stroke cases in Taiwan
Cheng, C., Kao, Y. Y., Lin, S., Lee, C., & Lai, M. L. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2087 · Cited by 1,277
Self-citationPleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,272
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y., Hsiao, C. K., Chen, P.-J., Chen, D.-S., & Chen, C.-J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013215 · Cited by 1,222
Self-citationRisk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease
Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282501 · Cited by 1,126
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P. D. R., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 816
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Statins Have Biphasic Effects on Angiogenesis
Weis, M., Heeschen, C., Glassford, A. J., & Cooke, J. P. (2002) · Circulation · doi:10.1161/hc0602.103393 · Cited by 680
The statins as anticancer agents.
Chan, K., Oza, A. M., & Siu, L. L. (2003) · PubMed · Cited by 618
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
Wong, W. W.-L., Dimitroulakos, J., Minden, M., & Penn, L. (2002) · Leukemia · doi:10.1038/sj.leu.2402476 · Cited by 578
Hippisley-Cox, J., & Coupland, C. (2010) · BMJ · doi:10.1136/bmj.c2197 · Cited by 512
HEBERT, P. R., GAZIANO, J. M., CHAN, K. S., & HENNEKENS, C. H. (1998) · Survey of Anesthesiology · doi:10.1097/00132586-199806000-00060 · Cited by 506
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin.
Keyomarsi, K., Sandoval, L. S., Band, V., & Pardee, A. B. (1991) · PubMed · Cited by 459
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Ye, J., Wang, C., Sumpter, R., Brown, M. S., Goldstein, J. L., & Gale, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2237238100 · Cited by 366
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1716 · Cited by 354
Rao, S., Porter, D. C., Chen, X., Herliczek, T., Lowe, M., & Keyomarsi, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7797 · Cited by 345
Chen, J., Yang, H., Iloeje, U. H., You, S., Lu, S., Wang, L., Su, J., Sun, C., Liaw, Y., & Chen, C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.042 · Cited by 331
Different anti-HCV profiles of statins and their potential for combination therapy with interferon
Ikeda, M., Abe, K.-I., Yamada, M., Dansako, H., Naka, K., & Kato, N. (2006) · Hepatology · doi:10.1002/hep.21232 · Cited by 313
Trebicka, J., Hennenberg, M., Laleman, W., Shelest, N., Biecker, E., Schepke, M., Nevens, F., Sauerbruch, T., & Heller, J. (2007) · Hepatology · doi:10.1002/hep.21673 · Cited by 305
Zafra, C., Abraldes, J. G., Turnes, J., Berzigotti, A., Fernández, M., Garcı́a-Pagán, J. C., Rodés, J., & Bosch, J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.007 · Cited by 297
El–Serag, H. B., Johnson, M. L., Hachem, C., & Morgana, R. O. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.053 · Cited by 291
Wu, C., Kuo, K. N., Wu, M., Chen, Y., Wang, C., & Lin, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.060 · Cited by 277
Cancer risk among statin users: A population‐based cohort study
Friis, S., Poulsen, A. H., Johnsen, S. P., McLaughlin, J. K., Fryzek, J. P., Dalton, S. O., Sørensen, H. T., & Olsen, J. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20758 · Cited by 275
Lewis, J. H., Mortensen, M. E., Zweig, S., Fusco, M. J., Medoff, J. R., & Belder, R. (2007) · Hepatology · doi:10.1002/hep.21848 · Cited by 248
Alsheikh-Ali, A. A., Maddukuri, P. V., Han, H., & Karas, R. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.073 · Cited by 241
Lai, M.-N., Wang, S.-M., Chen, P.-C., Chen, Y.-Y., & Wang, J.-D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp467 · Cited by 235
Self-citationDanesh, F. R., Sadeghi, M. M., Amro, N., Philips, C., Zeng, L., Lin, S., Sahai, A., & Kanwar, Y. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122228799 · Cited by 233
Statins and risk of cancer: A systematic review and metaanalysis
Browning, D. R. L., & Martin, R. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22366 · Cited by 228
Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort
Jacobs, E. J., Newton, C. C., Thun, M. J., & Gapstur, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2953 · Cited by 222
Statins and Liver Toxicity: A Meta‐Analysis
de Denus, S., Spinler, S. A., Miller, K., & Peterson, A. M. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.6.584.34738 · Cited by 220
Kusama, T., Mukai, M., Iwasaki, T., Tatsuta, M., Matsumoto, Y., Akedo, H., Inoue, M., & Nakamura, H. (2002) · Gastroenterology · doi:10.1053/gast.2002.31093 · Cited by 217
Blanco-Colio, L. M., Villa, A., Ortego, M., Hernández-Presa, M. A., Pascual, A., Plaza, J. J., & Egido, J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00613-x · Cited by 200
Serum triglyceride concentrations and cancer risk in a large cohort study in Austria
VHM & PP Study Group, Ulmer, H., Borena, W., Rapp, K., Klenk, J., Strasak, A., Diem, G., Concin, H., & Nagel, G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605264 · Cited by 199
Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.
Jasińska-Stroschein, M., Owczarek, J., & Orszulak–Michalak, D. (2007) · PubMed · Cited by 193
Chiang, C.-J., Chen, Y.-C., Chen, C.-J., You, S.-L., Lai, M.-S., & Taiwan Cancer Registry Task Force (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq057 · Cited by 190
Genotype‐specific mechanisms for hepatic steatosis in chronic hepatitis C infection
Hui, J. M., Kench, J., Farrell, G. C., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., & George, J. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02813.x · Cited by 178
Sassano, A., & Platanias, L. C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.11.036 · Cited by 168
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Arcaro, G., & Day, C. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.021 · Cited by 162
Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease
Lee, M.-H., Yang, H.-I., Wang, C.-H., Jen, C.-L., Yeh, S.-H., Liu, C.-J., You, S.-L., Chen, W. J., & Chen, C.-J. (2010) · Stroke · doi:10.1161/strokeaha.110.598136 · Cited by 160
Karp, I., Behlouli, H., LeLorier, J., & Pilote, L. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.12.011 · Cited by 151
Hepatitis B and C viruses in the development of hepatocellular carcinoma
Yu, M., & Chen, C. (1994) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)90020-5 · Cited by 137
Statin Use and the Risk of Liver Cancer: A Population-Based Case–Control Study
Chiu, H., Ho, S., Chen, C., & Yang, C. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.475 · Cited by 121
Reddy, B. S., Wang, C. X., Kong, A. T., Khor, T. O., Zheng, X., Steele, V. E., Kopelovich, L., & Rao, C. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4428 · Cited by 106
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment
Gopal, K., Johnson, T. C., Gopal, S. K., Walfish, A., Bang, C. T., Suwandhi, P., Sahdala, H. N. P., Clain, D. J., Bodenheimer, H. C., & Min, A. D. (2006) · Hepatology · doi:10.1002/hep.21261 · Cited by 105
Statins, stem cells, and cancer
Gauthaman, K., Fong, C., & Bongso, A. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22092 · Cited by 104
Microarray and Biochemical Analysis of Lovastatin-induced Apoptosis of Squamous Cell Carcinomas
Dimitroulakos, J., Marhin, W. H., Tokunaga, J., Irish, J., Gullane, P. J., Penn, L. Z., & Kamel‐Reid, S. (2002) · Neoplasia · doi:10.1038/sj.neo.7900247 · Cited by 97
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models
Shibata, M. (2003) · Carcinogenesis · doi:10.1093/carcin/24.3.453 · Cited by 92
Rombouts, K., Kisanga, E. R., Hellemans, K., Wielant, A., Schuppan, D., & Geerts, A. E. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00051-5 · Cited by 83
Hoffmeister, M., Chang-Claude, J. C., & Brenner, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.22796 · Cited by 80
Hippisley‐Cox, J., & Coupland, C. A. C. (2010) · Heart · doi:10.1136/hrt.2010.199034 · Cited by 71
Oberti, F., Pilette, C., Rifflet, H., Maiga, M. Y., Moreau, A., Gallois, Y., Girault, A., Bouil, A. L., Jeune, J. L., Saumet, J., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80473-4 · Cited by 55
Mallat, A., Préaux, A.-M., Blazejewski, S., et al. (1994) · Hepatology · doi:10.1002/hep.1840200631 · Cited by 32
Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus
Yang, X., Ronald, C. W., So, W. Y., Yu, L. W. L., Kong, A. P. S., Ko, G. T. C., Xu, G., Ozaki, R., Tong, P. C. Y., & Chan, J. C. N. (2010) · Cancer · doi:10.1002/cncr.25455 · Cited by 25
Cited by
Global Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & London, W. T. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.001 · Cited by 908
Wu, C.-Y., Chen, Y.-J., Ho, H. J., Hsu, Y.-C., Kuo, K. N., Wu, M.-S., & Lin, J.-T. (2012) · JAMA · doi:10.1001/2012.jama.11975 · Cited by 818
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
ATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017
Faludi, A., Izar, M., Saraiva, J., Chacra, A., Bianco, H., Afiune Neto, A., Bertolami, A., Pereira, A., Lottenberg, A., Sposito, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170121 · Cited by 633
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.005 · Cited by 452
Metadata
- Authors
- Tsan, Y.-T., Lee, C.-H., Wang, J.-D., & Chen, P.-C.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-02-20
- Volume
- 30
- Issue
- 6
- Pages
- 623-630
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2087556175
- Cited by
- 294
- References
- 61
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.